Low-Carbohydrate Diet for Blood Sugar
A low-carbohydrate diet reduces the starches and sugars in food, the part of a meal that the body turns into blood glucose, and makes up the energy with protein, fat and non-starchy vegetables. Research reviews sort these diets by how much carbohydrate is left: a low-carbohydrate diet is commonly set below 130 grams a day, and a very-low-carbohydrate or ketogenic diet at about 50 grams a day or less.
State of the evidence: many randomized trials in type 2 diabetes, pooled in several meta-analyses. They found a larger fall in hemoglobin A1C (HbA1c) on carbohydrate-restricted diets at 3 and 6 months. Most found little or no difference from the comparison diets at 12 months or later; one found a difference that lasted longer. One meta-analysis found more remission of type 2 diabetes at 6 months, a result that became smaller and non-significant when remission had to be reached without medication. The safety findings concern low blood sugar when insulin or sulfonylurea doses stay unchanged, ketoacidosis in people who take one class of diabetes drug on a ketogenic diet, and cholesterol. Type 1 diabetes is a separate case: no diet replaces insulin.
Table of Contents
What a Low-Carbohydrate Diet Is
Carbohydrate is the collective name for starches (grains, bread, rice, pasta, potatoes, beans and lentils), sugars (fruit, milk, honey, table sugar, sweetened drinks) and fiber. Digestion breaks starches and sugars down into glucose and other single sugars. Fiber passes through largely undigested.
There is no single agreed definition of "low-carbohydrate". Each review sets its own cut-offs, in grams a day or as a share of the day's energy (calories), so two reviews are not always describing the same diet. The table gives the cut-offs used by four of the reviews cited on this page.
| Review | Low-carbohydrate | Very-low-carbohydrate or ketogenic |
|---|---|---|
| 2021 meta-analysis of 23 trials (PMID 33441384) | Below 130 g a day, or below 26% of a 2000 kcal a day diet | Below 10% of calories from carbohydrate |
| 2022 Cochrane systematic review (PMID 35088407) | More than 50 g and up to 150 g a day, or below 45% of total energy | 50 g a day or less, or below 10% of total energy |
| 2022 meta-analysis of 8 trials (PMID 34338787) | Not studied | Below 50 g a day, or below 10% of total energy |
| 2022 meta-analysis of longer trials (PMID 36064937) | Not studied | 50 g a day or less, or 10% or less of total energy |
The Cochrane review called its comparison diets "balanced-carbohydrate", meaning 45% to 65% of total energy from carbohydrate (PMID 35088407). A 2023 network meta-analysis treated "moderate-carbohydrate" as a diet category of its own, separate from low-carbohydrate and ketogenic. Its abstract gives no cut-off for that category, so this page gives none (PMID 37513574).
"Ketogenic" describes what happens at the lowest intakes. With very little carbohydrate coming in, the body burns more fat, and the liver turns part of that fat into ketones, which the brain and muscles use as fuel. This state is called nutritional ketosis. It is not the same as diabetic ketoacidosis, a medical emergency described under Safety Findings.
Foods that carry little carbohydrate are whole foods such as meat, fish, eggs, cheese, butter, olive oil, nuts, seeds and non-starchy vegetables (leafy greens, broccoli, cauliflower, zucchini). The trial diets differed in what else they kept. In a 2022 randomized crossover trial, both diets tested included non-starchy vegetables and left out added sugars and refined grains. The ketogenic diet also left out legumes, fruits and whole, intact grains, while the Mediterranean-style diet it was compared with kept them (PMID 35641199).
How It Affects Blood Sugar
After a meal, glucose from digested starch and sugar enters the blood. The pancreas answers by releasing insulin, the hormone that moves glucose out of the blood into muscle, liver and fat cells. In type 2 diabetes the cells respond poorly to insulin (insulin resistance) and the pancreas cannot make enough to compensate, so blood sugar rises higher and stays up longer. Protein and fat raise blood sugar far less than carbohydrate does. A meal with less carbohydrate delivers less glucose, and less insulin is needed to clear it.
A 2025 dose-response meta-analysis of 38 articles (2831 participants with type 2 diabetes) asked whether a bigger cut brings a bigger effect. From the highest recorded carbohydrate intake (65%) down to 5%, each 10% decrease went with an improvement in HbA1c of 0.39% and in fasting glucose of 0.55 mmol/L. The significant effects came within the first 6 months and diminished after that. The improvements were not significantly affected by whether calories were restricted as well (PMID 40419389).
Weight loss is a second route. A 2023 network meta-analysis of 42 randomized trials (4809 people with type 2 diabetes) found that the average falls in HbA1c and fasting glucose across all the diets it compared were significantly related to one thing only: the average change in body weight (PMID 37513574). These two analyses point in different directions on how much of the effect comes from the carbohydrate itself and how much from weight loss. A 2021 meta-analysis found large, clinically important improvements in weight loss, triglycerides (blood fats) and insulin sensitivity at six months on low-carbohydrate diets, which diminished at 12 months (PMID 33441384).
What the Trials Found on Hemoglobin A1C
HbA1c is the blood test that reflects average blood sugar over roughly the previous three months. It is reported as a percentage. A randomized controlled trial assigns people by chance to one diet or another. A meta-analysis pools the results of several trials, and its authors often grade how much confidence the pooled result deserves, from high certainty down to very low. The findings in this section are in adults with type 2 diabetes unless stated. A minus sign means HbA1c was lower on the carbohydrate-restricted diet.
| Pooled analysis | Trials and people | Up to 6 months | 12 months or longer |
|---|---|---|---|
| Meta-analysis, 2022: very-low-carbohydrate ketogenic diet against recommended diets | 8 trials, 648 people | −0.61% at 3 months (moderate certainty); −0.58% at 6 months (low certainty) | Not better than the control diet after 12 months |
| Meta-analysis, 2022: very-low-carbohydrate diet against higher-carbohydrate diets, in prediabetes or type 2 diabetes | 8 trials, 606 people | Not given in the abstract | At 12 months: 0.01% in four studies (not significant); −0.65% in two studies |
| Meta-analysis, 2021: low-carbohydrate against low-fat diets, trials longer than 3 months | 12 trials, 761 people | 0.35% lower overall | Differences in HbA1c, triglycerides and high-density lipoprotein cholesterol "lasted up to 1.5 and 2 years" |
| Cochrane systematic review, 2022: low-carbohydrate against balanced-carbohydrate weight-reducing diets | 61 trials, 6925 people, most without type 2 diabetes | Not given for HbA1c in the abstract | In people with type 2 diabetes, probably little to no difference in HbA1c over 1 to 2 years |
| Network meta-analysis, 2023: ten diet patterns, trials of at least 6 months | 42 trials, 4809 people | Against a control diet: ketogenic −0.73, low-carbohydrate −0.69, low-fat −1.82 (the abstract states no unit) | |
The First Six Months
The short-term result is consistent. In the 2022 meta-analysis of eight randomized trials, the lower HbA1c at 3 and 6 months came with greater weight loss: 2.91 kg more than on recommended diets after 3 months and 2.84 kg more after 6 months (PMID 34338787). A 2021 meta-analysis of 12 randomized trials (761 patients) that compared low-carbohydrate with low-fat diets found HbA1c 0.35% lower and weight loss 2.99 kg greater on the low-carbohydrate diets (PMID 34912453).
Twelve Months and Beyond
By 12 months the difference narrows. The same 2022 meta-analysis reported that the very-low-carbohydrate ketogenic diet "was not better than a control diet after 12 months". It stayed ahead for up to 12 months on three other measures: lower triglycerides, higher high-density lipoprotein (HDL) cholesterol and less use of antidiabetic medication. The authors named poor adherence to carbohydrate restriction as a major limitation and wrote that the quality of the available evidence "is not sufficient to recommend" the diet (PMID 34338787).
A second 2022 meta-analysis took HbA1c at 12 months as its main outcome and included only trials of at least 6 months. Six studies reported it. Four of them, pooled, gave a difference of 0.01% (p = .91), which is no difference. The other two, pooled separately, gave −0.65%. Triglycerides were 0.28 mmol/L lower on the very-low-carbohydrate diets. The authors concluded that such a diet may reduce HbA1c and triglycerides "but evidence of an advantage over other strategies is limited" (PMID 36064937).
The 2022 Cochrane review compared low-carbohydrate with balanced-carbohydrate weight-reducing diets. In people with type 2 diabetes it found probably little to no difference in body weight over three to six months (14 trials, 1114 participants) or over one to two years (7 trials, 813 participants), and probably little to no difference in HbA1c, diastolic blood pressure or low-density lipoprotein cholesterol over one to two years. The reviewers judged the risk of bias across the trials to be predominantly high (PMID 35088407).
One meta-analysis found a longer-lasting difference. In the 2021 comparison with low-fat diets, subgroup analyses showed that the differences in HbA1c, triglycerides and HDL cholesterol "lasted up to 1.5 and 2 years", while the weight difference shrank over time and disappeared after 2 years (PMID 34912453).
Compared With Other Diet Patterns
A network meta-analysis compares many diets with one another through a shared control diet. The 2023 analysis found three patterns significantly better than a control diet for HbA1c: ketogenic, low-carbohydrate and low-fat (figures in the table). The authors' conclusion, which took fasting glucose into account as well, named the ketogenic, Mediterranean, moderate-carbohydrate and low glycemic index diets as effective options and stated that further high-quality, long-term studies are needed (PMID 37513574).
A single randomized crossover trial from 2022 shows how much depends on the comparison diet. Forty adults with prediabetes or type 2 diabetes followed a ketogenic diet and a Mediterranean-style diet for 12 weeks each, in random order; 33 had complete data. HbA1c improved from baseline on both diets and did not differ between them at 12 weeks. Triglycerides fell more on the ketogenic diet (−16% against −5%). Low-density lipoprotein cholesterol rose on the ketogenic diet and fell on the other (+10% against −5%). Follow-up data suggested the Mediterranean-style diet was the more sustainable (PMID 35641199).
On weight alone, a 2022 umbrella review of 19 published meta-analyses of weight-loss diets in type 2 diabetes found low-carbohydrate diets "no better for weight loss than higher-carbohydrate/low-fat diets", a finding it rated as high quality and high certainty (PMID 34796367).
What the Trials Found on Remission
Remission means blood sugar measures that have returned below the diabetes threshold. How it is defined changes the result, so each finding below is given with the definition its authors used.
The largest pooled analysis is a 2021 systematic review and meta-analysis of 23 randomized trials (1357 participants) of diets followed for at least 12 weeks, with searches run to 25 August 2020. Its definition of remission was an HbA1c below 6.5% or a fasting glucose below 7.0 mmol/L, with or without the use of diabetes medication. At six months, with remission defined as HbA1c below 6.5%, 76 of 133 people (57%) on low-carbohydrate diets had reached it against 41 of 131 (31%) on control diets: a risk difference of 0.32 (95% confidence interval, the range the true value probably lies in, 0.17 to 0.47; 8 studies, 264 people) (PMID 33441384).
The same analysis reported four qualifications:
- When remission was defined as HbA1c below 6.5% without medication, the effect sizes were smaller and not statistically significant.
- Remission with low-carbohydrate diets "markedly decreased" in studies that included people using insulin.
- At 12 months the data on remission were sparse, "ranging from a small effect to a trivial increased risk of diabetes".
- The certainty of the evidence was moderate to low, and 40.6% of outcomes were judged to be at low risk of bias. The authors listed the continuing debate over what counts as remission among the limitations.
The 2022 umbrella review also gathered intervention studies that reported remission. For ketogenic or very-low-carbohydrate diets it found remission in 20% of participants, from evidence with serious and critical risk of bias and very low certainty. For comparison, randomized trials that began with a low-energy total diet replacement phase reported remission at 1 year in a median 54% of participants (high certainty), and the figures for meal replacements and Mediterranean diets were 11% and 15%. The review concluded that published meta-analyses of reduced-calorie diets "do not support any particular macronutrient profile or style over others" (PMID 34796367).
A 2025 systematic review looked only at studies with at least 12 months of follow-up. It found six, randomized and non-randomized, lasting one to eight years. Remission rates were highest at one year (up to 62%) and declined to 13% by year five, with some weight regain and return of high blood sugar over time. People on the diets also came to depend less on glucose-lowering and blood-pressure medication. The abstract does not state the definition of remission the review used (PMID 41020034).
What Guidelines and Consensus Reports State
A consensus report on nutrition therapy for adults with diabetes or prediabetes was published in the journal Diabetes Care in 2019 (PMID 31000505). Its PubMed record carries no abstract, and this page is built only from PubMed records, so no statement from that report is given here.
A 2021 review on adjusting diabetes medication, which its authors describe as an international consensus document written by a multidisciplinary team of clinicians, states that the American Diabetes Association, in its Standards of Medical Care in Diabetes for 2021, acknowledges low-carbohydrate nutrition therapy as a viable option in the management of type 2 diabetes. The same review states that there is minimal guidance in the literature on how to reduce medication as blood sugar improves (PMID 34434951).
Findings in Type 1 Diabetes
Type 1 diabetes is a state of absolute insulin deficiency: the pancreas makes little or no insulin. No diet, food or herb replaces insulin. Without insulin, diabetic ketoacidosis develops, and it is fatal if untreated. The studies below measured what happened to blood sugar and insulin doses when people with type 1 diabetes ate less carbohydrate alongside insulin treatment. The evidence is much thinner than for type 2 diabetes.
A 2018 systematic review found nine studies in which carbohydrate was below 45% of total energy for at least two weeks: two randomized controlled trials, four before-and-after studies, two case series and one case report. Eight reported a mean change in HbA1c. Of these, the abstract counts four with a non-significant change and three with statistically significant reductions. Two studies reported on severe low blood sugar. Because the studies differed so much, the reviewers could not determine an overall effect, and they wrote of an urgent need for more primary studies (PMID 29596460).
A 2025 systematic review of nine clinical trials found low-carbohydrate diets associated with more time in the target glucose range on continuous glucose monitoring (+5.68%), less time below range (−0.53% at a 54 mg/dL threshold and −2.28% at a 70 mg/dL threshold), steadier glucose (coefficient of variation −5.51%), a lower total daily insulin dose (−8.39%) and lower systolic blood pressure (−4.83 mmHg). The authors described this as potential benefit that warrants robust clinical trials, and called the role of these diets in type 1 diabetes still controversial (PMID 40097047).
A 2023 review of benefits and risks reported four things. Many studies show improved HbA1c, more time in the target range and less glucose variability. A lipid pattern with high low-density lipoprotein cholesterol is observed in many patients, and its link to future cardiovascular events is undefined. A negative effect on growth has been identified in children. Effects on mental health and disordered eating are a theoretical concern that clinical studies have not measured (PMID 36668976).
Safety Findings
Low Blood Sugar When Drug Doses Stay the Same
Insulin and sulfonylurea drugs (which make the pancreas release more insulin) lower blood sugar whatever has been eaten. A dose matched to a higher-carbohydrate diet keeps working at full strength when the carbohydrate is cut, and blood sugar can fall too low (hypoglycemia). Signs of low blood sugar are shakiness, sweating, fast heartbeat and confusion, and at lower levels seizure or loss of consciousness.
The 2021 consensus document on adjusting medication states that starting a low-carbohydrate diet in people who take medication requires significant monitoring and medication adjustments to decrease and eliminate the risk of hypoglycemia and of hypotension (low blood pressure). It names the most immediate and important adjustments as those to insulin, sulfonylureas, sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors), blood pressure medications and diuretics (PMID 34434951). The 2021 meta-analysis of 23 trials found no significant or clinically important difference in adverse events between the diet groups at six and 12 months (PMID 33441384).
Ketoacidosis With Near-Normal Blood Sugar
Diabetic ketoacidosis is a dangerous build-up of ketones and acid in the blood. It usually comes with very high blood sugar. SGLT2 inhibitors are type 2 diabetes drugs that make the kidneys pass glucose out in the urine. They carry a rare risk of ketoacidosis at normal or only slightly raised glucose values, called euglycemic diabetic ketoacidosis (PMID 33851013). Because blood sugar is near normal, a glucose reading does not reveal it. Its symptoms include nausea, vomiting, abdominal pain, fast deep breathing and unusual tiredness.
A 2021 case series described two people with type 2 diabetes who developed this condition while taking an SGLT2 inhibitor and eating a ketogenic diet. One developed it after a single dose of the drug; the other after one week on the diet while already taking the drug. Both had normal or mildly elevated blood glucose together with ketosis. The authors wrote that many prescribers may not be aware of the association (PMID 33851013).
A 2024 review of the United States Food and Drug Administration's adverse event reports and the medical literature identified 29 cases of prolonged or relapsed ketoacidosis, or of persistent ketones or glucose in the urine, in adults with type 2 diabetes taking SGLT2 inhibitors, reported through July 26, 2022. Treatment lasted from 3 to 20 days. The associated factors included surgery, decreased calorie intake and a ketogenic or carbohydrate-restricted diet. All patients with sufficient follow-up information recovered. The cases led to updates to the prescribing information for these drugs (PMID 38692489).
Low-Density Lipoprotein Cholesterol
Low-density lipoprotein (LDL) cholesterol is the cholesterol measure most often used to gauge cardiovascular risk. The findings differ by who was studied. The crossover trial described above found a 10% rise after 12 weeks of a ketogenic diet, and the 2023 review of type 1 diabetes reported high LDL cholesterol in many patients.
- Type 2 diabetes, pooled trials. A 2022 meta-analysis of ten articles found no significant difference in total, HDL or LDL cholesterol between very-low-carbohydrate ketogenic diets and control diets, at 3, 6 or 12 months. Triglycerides fell markedly at 3 months, with no significant difference at 6 and 12 months (PMID 35243868).
- Type 2 diabetes, 12 months. The 2021 meta-analysis of 23 trials reported a "clinically important, but not statistically significant" worsening of LDL cholesterol and of quality of life at 12 months (PMID 33441384).
- Body weight matters. A 2024 meta-analysis of 41 randomized trials (1379 adults eating less than 130 g of carbohydrate a day; the abstract does not say how many had diabetes) sorted the trials by average body mass index (BMI), a measure of weight for height. In trials with an average BMI below 25, LDL cholesterol rose by 41 mg/dL. With an average BMI of 25 to below 35 it did not change. With an average BMI of 35 or more it fell by 7 mg/dL. The amount of saturated fat eaten was not significantly associated with the change. The authors wrote that the clinical significance of an isolated rise in LDL cholesterol in this setting "warrants investigation" (PMID 38237807).
Fiber, Kidney Measures and Reported Side Effects
In the 2022 crossover trial, participants took in less fiber and less of three nutrients on the ketogenic diet than on the Mediterranean-style diet, which the authors linked to leaving out legumes, fruits and whole, intact grains (PMID 35641199). The 2021 meta-analysis against low-fat diets found no significant difference in serum creatinine, a blood test of kidney function, and stated that the available data are insufficient to evaluate kidney safety (PMID 34912453). The Cochrane reviewers found the evidence on side effects reported by participants too limited to draw any conclusion (PMID 35088407).
Limits of the Evidence
- Short follow-up. The 2022 umbrella review states that most of the evidence is restricted to 1 year or less and that research is needed on longer-term effects on weight, blood sugar control, clinical outcomes and diabetes complications (PMID 34796367). The abstracts cited on this page report blood tests, weight and remission. None reports heart attacks, kidney failure, nerve damage or eye disease as outcomes.
- Adherence. One meta-analysis names lack of adherence to carbohydrate restriction as a major limitation (PMID 34338787). Another found very-low-carbohydrate diets less effective for weight loss at six months than less restrictive low-carbohydrate diets, an effect explained by adherence (PMID 33441384).
- Trial quality. The Cochrane review rated the risk of bias as predominantly high, mostly because of missing outcome data, and the certainty of evidence as moderate to very low (PMID 35088407).
- Shifting definitions. The carbohydrate cut-offs differ from review to review, the comparison diets differ (low-fat, Mediterranean, "recommended", "balanced"), and the definition of remission is itself debated.
- Diet alongside medication. Reviews report less use of glucose-lowering medication on these diets (PMID 34338787, PMID 41020034). The abstracts do not describe a trial that tested the diet in place of medication.
Key Research Papers
- Goldenberg JZ, Day A, Brinkworth GD, Sato J, Yamada S, Jönsson T, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021;372:m4743. PubMed PMID: 33441384
- Rafiullah M, Musambil M, David SK. Effect of a very low-carbohydrate ketogenic diet vs recommended diets in patients with type 2 diabetes: a meta-analysis. Nutr Rev. 2022;80(3):488-502. PubMed PMID: 34338787
- Parry-Strong A, Wright-McNaughton M, Weatherall M, Hall RM, Coppell KJ, Barthow C, et al. Very low carbohydrate (ketogenic) diets in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2022;24(12):2431-2442. PubMed PMID: 36064937
- Lan J, Chen M, Zhang X, Yang J. Effect of dietary carbohydrate intake on glycaemic control and insulin resistance in type 2 diabetes: A systematic review and meta-analysis. Asia Pac J Clin Nutr. 2025;34(3):282-297. PubMed PMID: 40419389
- Naude CE, Brand A, Schoonees A, Nguyen KA, Chaplin M, Volmink J. Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk. Cochrane Database Syst Rev. 2022;1(1):CD013334. PubMed PMID: 35088407
- Li S, Ding L, Xiao X. Comparing the Efficacy and Safety of Low-Carbohydrate Diets with Low-Fat Diets for Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Int J Endocrinol. 2021;2021:8521756. PubMed PMID: 34912453
- Jing T, Zhang S, Bai M, Chen Z, Gao S, Li S, et al. Effect of Dietary Approaches on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review with Network Meta-Analysis of Randomized Trials. Nutrients. 2023;15(14):3156. PubMed PMID: 37513574
- Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022;65(1):14-36. PubMed PMID: 34796367
- Das R, Mohammad N, Islam MS, Das S, Abdullah F, Kader MA, et al. Long-Term Efficacy and Safety of a Low-Carbohydrate Diet in Type 2 Diabetes Remission: A Systematic Review. Cureus. 2025;17(9):e93340. PubMed PMID: 41020034
- Gardner CD, Landry MJ, Perelman D, Petlura C, Durand LR, Aronica L, et al. Effect of a ketogenic diet versus Mediterranean diet on glycated hemoglobin in individuals with prediabetes and type 2 diabetes mellitus: The interventional Keto-Med randomized crossover trial. Am J Clin Nutr. 2022;116(3):640-652. PubMed PMID: 35641199
- Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019;42(5):731-754. PubMed PMID: 31000505
- Cucuzzella M, Riley K, Isaacs D. Adapting Medication for Type 2 Diabetes to a Low Carbohydrate Diet. Front Nutr. 2021;8:688540. PubMed PMID: 34434951
- Mistry S, Eschler DC. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature. AACE Clin Case Rep. 2021;7(1):17-19. PubMed PMID: 33851013
- Woronow D, Chamberlain C, Houstoun M, Muñoz M. Prolonged Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Postmarketing Cases. Endocr Pract. 2024;30(7):603-609. PubMed PMID: 38692489
- Soto-Mota A, Flores-Jurado Y, Norwitz NG, Feldman D, Pereira MA, Danaei G, et al. Increased low-density lipoprotein cholesterol on a low-carbohydrate diet in adults with normal but not high body weight: A meta-analysis. Am J Clin Nutr. 2024;119(3):740-747. PubMed PMID: 38237807
- Li M, Yuan J. Effects of very low-carbohydrate ketogenic diet on lipid metabolism in patients with type II diabetes mellitus: a meta-analysis. Nutr Hosp. 2022;39(4):916-923. PubMed PMID: 35243868
- Turton JL, Raab R, Rooney KB. Low-carbohydrate diets for type 1 diabetes mellitus: A systematic review. PLoS One. 2018;13(3):e0194987. PubMed PMID: 29596460
- Sousa SSS, Nery ES, Giuffrida FMA. Low-carbohydrate diet in type 1 diabetes: A systematic review. Clin Nutr ESPEN. 2025;67:250-256. PubMed PMID: 40097047
- Hancock M, Burns K, Gan SK, Chew GT. Low-carbohydrate diets in type 1 diabetes: balancing benefits and risks. Curr Opin Endocrinol Diabetes Obes. 2023;30(2):113-122. PubMed PMID: 36668976
PubMed Topic Searches
Connections
- Diabetes
- Blood Sugar Remedies
- Type 2 Diabetes
- Insulin Resistance
- Ketogenic Diet
- Type 2 Diabetes Remission and Reversal Strategies
- Reversing Insulin Resistance: Diet and Fasting Protocols
- Intermittent Fasting for Blood Sugar
- Glycemic Index and Glycemic Load
- Hemoglobin A1C
- Hypoglycemia Awareness and Prevention
- Type 1 Diabetes